NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Zynex, Inc. (NASDAQ: ZYXI) between March 13, 2023 and March 11, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025. SO WHAT: If you purchased Zynex securities during the Class Period you ...

Core Viewpoint - Zynex, Inc. is facing a securities class action lawsuit due to alleged misleading statements and undisclosed adverse information regarding its business operations, particularly related to revenue shortfalls and payment issues from key payers like Tricare [3][4][7]. Company Overview - Zynex, Inc. develops, manufactures, and markets medical devices focused on pain management and rehabilitation, specializing in electrotherapy technology for non-invasive pain relief and muscle stimulation [3]. Financial Performance - On March 11, 2025, Zynex reported a significant revenue shortfall for the fourth quarter and full year 2024, attributing it to slower payments from certain payers, with Tricare temporarily suspending payments, which constitutes approximately 20-25% of Zynex's annual revenue [4]. Allegations and Misconduct - The complaint alleges that during the class period, Zynex engaged in practices such as shipping products in excess of patient needs, inflating revenue through these shipments, and filing questionable claims that drew scrutiny from insurers [7]. - These practices led to significant risks, including potential removal from insurer networks and federal penalties, making the defendants' statements about Zynex's business and prospects materially misleading [7].

ATLANTA, March 25, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Zynex, Inc. (“Zynex” or the “Company”) (NASDAQ: ZYXI). The lawsuit alleges that Defendants made materially false and/or misleading statements and/or failed to disclose material adverse facts regarding Zynex’s business, operations, and prospects, including allegations that: (1) Zynex shipped products, including electrodes, in excess of need; (2) as a result of this practice, the Company inflated its revenue; ...

LOS ANGELES, March 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Zynex, Inc. ("Zynex" or "the Company") (NASDAQ: ZYXI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between March 13, 2023 to March 11, 2025, inclusive (the "Class Period"), are encoura ...

Core Viewpoint - A class action lawsuit has been filed against Zynex, Inc. for allegedly making false and misleading statements regarding its business practices and financial performance during the specified Class Period [1][3]. Summary by Relevant Sections Class Action Details - The lawsuit is filed on behalf of all individuals and entities who purchased Zynex securities between March 13, 2023, and March 11, 2025, with a deadline of May 19, 2025, for investors to apply as lead plaintiffs [1]. Allegations Against Zynex - The complaint alleges that Zynex shipped products, including electrodes, in excess of actual need, leading to inflated revenue figures [3]. - It is claimed that Zynex's practice of filing false claims attracted scrutiny from insurers, including Tricare, which could result in adverse consequences such as removal from insurer networks and federal penalties [3]. - The lawsuit asserts that the positive statements made by Zynex regarding its business and prospects were materially misleading and lacked a reasonable basis due to the undisclosed practices [3].

NEW YORK, March 24, 2025 /PRNewswire/ --Why: Rosen Law Firm, a global investor rights law firm, announces that an investor filed a class action on behalf of persons or entities who purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 and March 11, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than May 19, 2025.So What: If you purchased Zynex secur ...

SAN DIEGO, March 21, 2025 /PRNewswire/ -- Robbins LLP informs stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Zynex, Inc. (NASDAQ: ZYXI) securities between March 13, 2023 to March 11, 2025. Zynex is a medical device manufacturer that produces and markets electrotherapy devices for use in pain management and physical rehabilitation.For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (800) 350-6003.The All ...

Core Viewpoint - Zynex, Inc. is under investigation for potential securities fraud and unlawful business practices following a significant revenue shortfall and a major drop in stock price due to payment issues from key payers [1][2]. Financial Performance - Zynex reported a revenue shortfall in Q4 2024 attributed to slower than normal payments from certain payers [2]. - The company disclosed that Tricare, which accounts for approximately 20-25% of its annual revenue, has temporarily suspended payments while reviewing prior claims [2]. - Following this announcement, Zynex's stock price plummeted by $3.59 per share, or 51.3%, closing at $3.41 per share on March 12, 2025 [2]. Legal Context - Pomerantz LLP is investigating claims on behalf of Zynex investors regarding possible securities fraud or other unlawful business practices by the company and its officers/directors [1]. - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [3].

NEW YORK, March 14, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Zynex, Inc. ("Zynex" or the "Company") (NASDAQ:ZYXI). The investigation concerns whether Zynex and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices. [LEARN MORE ABOUT THE INVESTIGATION] On March 11, 2025, after market hours, Zynex released its fourth quarter and full year 2024 financial results, revealing a revenue ...

Core Insights - Zynex, Inc. reported lower than expected revenue for the fourth quarter and full year ended December 31, 2024, primarily due to slower payments from certain payers and a temporary suspension of payments by Tricare as they review prior claims [1] Company Summary - Zynex, Inc. is currently under investigation by Holzer & Holzer, LLC to determine if the company complied with federal securities laws following the disappointing financial results announcement [1] - The announcement of the revenue shortfall led to a decline in Zynex's stock price [1] Legal Context - Holzer & Holzer, LLC is a law firm specializing in representing shareholders and investors in securities litigation, including class action and derivative litigation [3] - The firm has a history of recovering significant amounts for shareholders affected by corporate misconduct [3]